TEV 90112Alternative Names: TEV-90112
Latest Information Update: 27 Nov 2014
At a glance
- Originator Teva Pharmaceutical Industries
- Class Antivirals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections
Most Recent Events
- 01 Oct 2014 Phase-I clinical trials in HIV infections in Israel (unspecified route) prior to October 2014